Topic: Fierce 15

Fierce 15

FierceBiotech's 2019 Fierce 15

This has been a year for IPOs and buyouts—but private and independent preclinical biotechs are our focus, and we honor them with our Fierce 15 award.

Prelude Therapeutics

By blocking an enzyme linked to epigenetic regulation, Prelude hopes to cut off certain treatment-resistant cancers from the DNA splicing and proliferative mechanics necessary for tumor growth and survival.

Sanifit

Sanifit is breaking the mold in its native country: Back in June, it raised a massive €55.2 million ($62.9 million) series D round, smashing Spanish biotech VC records and ranking as one of the biggest life sciences raises in Europe for the year.

Quell Therapeutics

Quell has brought together experts in multiple fields to probe a question with far-reaching implications: What would happen if we applied CARs and other cell enhancements to regulatory T cells rather than effector T cells?

Nocion Therapeutics

While whole shoals of biotechs are clustered around single cancer targets, Nocion is away from the pack working on better ways to treat conditions such as cough and itch.

Nkarta Therapeutics

The commercial potential of CAR-Ts is constrained by a range of logistical and safety issues. Nkarta thinks engineered natural killer cells can eliminate those constraints, resulting in better therapies equipped to go mainstream.

Maze Therapeutics

Rather than targeting gene-gene interactions that kill cells, Maze is going after genetic combinations that stop people from developing deleterious phenotypes.